<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202020000100104</article-id>
<article-id pub-id-type="doi">10.29277/cardio.35.1.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Prevención de trombosis protésica con anticoagulación luego de sustitución valvular aórtica con bioprótesis. Metaanálisis]]></article-title>
<article-title xml:lang="en"><![CDATA[Prevention of prosthetic thrombosis with anticoagulation after aortic valve replacement with bioprosthesis. Meta-analysis]]></article-title>
<article-title xml:lang="pt"><![CDATA[Prevenção de trombose protética com anticoagulação após troca valvar aórtica por bioprótese. Meta-análise]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tabó]]></surname>
<given-names><![CDATA[Julia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Resquin]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[Analía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Umpiérrez]]></surname>
<given-names><![CDATA[Leticia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urrutia]]></surname>
<given-names><![CDATA[Romina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dayan]]></surname>
<given-names><![CDATA[Víctor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Clínicas Centro Cardiovascular Universitario Departamento de Cirugía Cardíaca]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>35</volume>
<numero>1</numero>
<fpage>104</fpage>
<lpage>130</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202020000100104&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202020000100104&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202020000100104&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Antecedentes:  se ha reportado mayor riesgo de trombosis y eventos clínicos en pacientes que reciben bioprótesis luego de sustitución quirúrgica de la válvula aórtica, o del implante transcatéter (TAVI).  Objetivo:  evaluar si el uso de anticoagulación oral (ACO), como mínimo por 90 días, disminuye o previene la aparición de eventos clínicos tromboembólicos o trombosis subclínica, en pacientes con sustitución valvular aórtica biológica. Evaluar el sangrado y mortalidad asociados con esta estrategia.  Método:  se efectuó una búsqueda de artículos en bases de datos PubMed, Cochrane Central, Biblioteca Cochrane y SciELO. Los términos utilizados fueron: &#8220;Anticoagulation AND aortic bioprosthesis&#8221; y &#8220;Anticoagulation AND TAVI OR TAVR&#8221;. Se establecieron criterios de inclusión y exclusión, y se realizó el análisis de eventos clínicos y subclínicos por separado. El estadístico utilizado fue odds ratio (OR). Se usó un modelo de efectos randomizados para calcular el estadístico y su intervalo de confianza (IC) de 95%. Los resultados del metaanálisis se presentaron como diagrama de bosque. Consideramos significativa una p&lt;0,05.  Resultados:  se identificaron 233 artículos; seleccionando ocho para trombosis clínica y cinco para trombosis subclínica. No se evidenció diferencia significativa en la incidencia de eventos embólicos con el uso de ACO (OR=1,01; IC95%: 0,63-1,61; p=0,98), ni de mortalidad a corto plazo (OR=1,10; IC95%: 0,77-1,56; p=0,61). Se demostró una superior incidencia de sangrados mayores en pacientes que recibieron ACO (OR=1,60; IC95%: 1,04-2,48; p=0,03). El riesgo de trombosis subclínica protésica fue mayor en pacientes que no recibieron ACO (OR=5,52; IC95%: 3,37-9,05; p=0,001).  Conclusiones:  la ACO se asocia a un menor riesgo de trombosis protésica subclínica aumentando el riesgo de sangrado. En los grupos comparados no existe diferencia en mortalidad o fenómenos embólicos a mediano plazo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Background:  increased risk of thrombosis and clinical events has been reported in patients receiving bioprostheses after aortic valve replacement or transcatheter aortic valve implant.  Objective: to assess whether the use of anticoagulation for at least 90 days decreases and / or prevents occurrence of thrombo-embolic or subclinical thrombosis in patients with biological aortic valve replacement. To evaluate the incidence of bleeding and mortality associated with this strategy.  Methods: we searched articles in databases: PubMed, Central Cochrane, Cochrane Library and SciELO. The terms used were: &#8220;Anticoagulation AND aortic bioprosthesis&#8221; and &#8220;Anticoagulation AND TAVI OR TAVR&#8221;. Inclusion and exclusion criteria were established, performing the analysis of clinical and subclinical events separately. The statistic used was odds ratio (OR). A randomized effects model was used to calculate the statistic and its 95% confidence interval (CI). The meta-analysis results were presented as a forest diagram. We consider p &lt;0.05 significant.  Results: 233 articles were identified; selecting 8 for clinical thrombosis and 5 for subclinical thrombosis. There was no significant difference in the incidence of embolic events with the use of oral anticoagulation (OR = 1.01; 95% CI: 0.63-1.61;p = 0.98) or short-term mortality (OR = 1.10; 95% CI: 0.77-1.56;p = 0.61). A higher incidence of major bleeding was demonstrated in patients receiving oral anticoagulation (OR = 1.60; 95% CI: 1.04-2.48; p = 0.03). The risk of subclinical prosthetic thrombosis was higher in patients who did not receive oral anticoagulation (OR = 5.52; 95% CI: 3.37-9.05; p = 0.001).  Conclusions:  oral anticoagulation is associated with a lower risk of subclinical prosthetic thrombosis, increasing the risk of bleeding. Between the groups compared, there is no difference in mortality or embolic phenomena at medium term.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Antecedentes: foi relatado maior risco de trombose e eventos clínicos em pacientes que receberam biopróteses após substituição cirúrgica ou implante transcateter.  Objetivo: avaliar se o uso de anticoagulação por pelo menos 90 dias diminui e / ou impede a ocorrência de eventos clínicos tromboembólicos ou subclínicos em pacientes com substituição da válvula aórtica biológica. Avaliar a incidência de sangramento e mortalidade associados a essa estratégia.  Métodos: pesquisamos artigos nas bases de dados: PubMed, Central Cochrane, Cochrane Library e SciELO. Os termos utilizados foram: &#8220;Anticoagulation AND aortic bioprosthesis&#8221; e &#8220;Anticoagulation AND TAVI OR TAVR&#8221;. Os critérios de inclusão e exclusão foram estabelecidos, realizando a análise dos eventos clínicos e subclínicos separadamente. A estatística utilizada foi odds ratio (OR). Um modelo de efeitos randomizados foi utilizado para calcular a estatística e seu intervalo de confiança de 95% (IC). Os resultados da metanálise foram apresentados como um diagrama florestal. Consideramos p &lt;0,05 significativo.  Resultados: foram identificados 233 artigos; selecionando 8 para trombose clínica e 5 para trombose subclínica. Não houve diferença significativa na incidência de eventos embólicos com o uso de ACO (OR = 1,01; IC95%: 0,63-1,61; p = 0,98) ou mortalidade a curto prazo (OR = 1,10; IC95%: 0,77-1,56; p = 0,61). Uma incidência maior de sangramento maior foi demonstrada em pacientes que receberam anticoagulação (OR = 1,60; IC95%: 1,04-2,48; p = 0,03). O risco de trombose protética subclínica foi maior nos pacientes que não receberam anticoagulação (OR = 5,52; IC 95%: 3,37-9,05; p = 0,001).  Conclusões: a anticoagulação oral está associada a um menor risco de trombose protética subclínica, aumentando o risco de sangramento. Nos grupos comparados, não há diferença na mortalidade ou no fenômeno embólico a médio prazo.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Reemplazo de la válvula aórtica transcatéter]]></kwd>
<kwd lng="es"><![CDATA[Bioprótesis]]></kwd>
<kwd lng="es"><![CDATA[Trombosis]]></kwd>
<kwd lng="es"><![CDATA[Anticoagulantes]]></kwd>
<kwd lng="en"><![CDATA[Transcatheter aortic valve replacement]]></kwd>
<kwd lng="en"><![CDATA[Bioprosthesis]]></kwd>
<kwd lng="en"><![CDATA[Thrombosis]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulants]]></kwd>
<kwd lng="pt"><![CDATA[Substituição da valva aórtica transcateter]]></kwd>
<kwd lng="pt"><![CDATA[Bioprótese]]></kwd>
<kwd lng="pt"><![CDATA[Trombose]]></kwd>
<kwd lng="pt"><![CDATA[Anticoagulantes]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Sociedad Argentina de Cardiología</collab>
<article-title xml:lang=""><![CDATA[Área de Normatizaciones y Consenso Sociedad Argentina de Gerontología y Geriatría. Valvulopatías aórticas]]></article-title>
<source><![CDATA[Rev Argent Cardiol]]></source>
<year>2003</year>
<volume>71</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>38-44</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mydin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dimitrakakis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Younis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nowell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Athanasiou]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kourliouros]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal thromboprophylaxis following bioprosthetic aortic valve replacement still a matter of debate?]]></article-title>
<source><![CDATA[Interact Cardiovasc Thorac Surg]]></source>
<year>2012</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>109-14</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordoba-Soriano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Amat-Santos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Abdul-Jawad]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[del Trigo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión sistemática de la trombosis protésica tras implante percutáneo de válvula aórtica]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>198-204</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jilaihawi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imaging evaluation for the detection of leaflet thrombosis after transcatheter aortic valve replacement]]></article-title>
<source><![CDATA[Interv Cardiol Clin]]></source>
<year>2018</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>293-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kappetein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Head]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Généreux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Piazza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[van Mieghem]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Blackstone]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Updated standardized endpoint definitions for transcatheter aortic valve implantation the Valve Academic Research Consortium-2 consensus document]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2012</year>
<volume>33</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2403-18</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chakravarty]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Søndergaard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Berman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kofoed]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves an observational study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10087</numero>
<issue>10087</issue>
<page-range>2383-92</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evangelista]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comentarios a la guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2018</year>
<volume>71</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>67-73</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishimura]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Otto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carabello]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2017 AHA/ACC Focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines]]></article-title>
<collab>Erwin J3rd.Fleisher L</collab>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>135</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>e1159-95</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yanagisawa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hayashida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yashima]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Inohara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Trigo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Latib]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Auffret]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wijeysundera]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nombela-Franco]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of anticoagulation therapy on valve haemodynamic deterioration following transcatheter aortic valve replacement]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2018</year>
<volume>104</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>814-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Grove]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Leipsic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mathiassen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transcatheter aortic valve thrombosis incidence, predisposing factors, and clinical implications]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2016</year>
<volume>68</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2059-69</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jose]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sulimov]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[El-Mawardy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Allali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement incidence, characteristics, and treatment outcomes]]></article-title>
<source><![CDATA[JACC Cardiovasc Interv]]></source>
<year>2017</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>686-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early anticoagulation of bioprosthetic aortic valves in older patients results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database]]></article-title>
<collab>O'Brien S.Booth M.Dokholyan R</collab>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2012</year>
<volume>60</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>971-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ElBardissi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[DiBardino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2010</year>
<volume>139</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1137-45</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aceves-Velázquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vieyra-Herrera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Chávez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la estrategia de terapia antitrombótica posterior al cambio valvular aórtico con válvulas biológicas en pacientes de bajo riesgo trombótico]]></article-title>
<source><![CDATA[Arch Cardiol Méx]]></source>
<year>2017</year>
<volume>88</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>339-46</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[di Marco]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grendene]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Feltrin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Meneghetti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gerosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiplatelet therapy in patients receiving aortic bioprostheses a report of clinical and instrumental safety]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2007</year>
<volume>133</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1597-603</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gherli]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Colli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fragnito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Borrello]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Saccani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing warfarin with aspirin after biological aortic valve replacement a prospective study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>110</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>496-500</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Atassi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Forgie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Boodhwani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubens]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hendry]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebral microembolization after bioprosthetic aortic valve replacement comparison of warfarin plus aspirin versus aspirin only]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>126</volume>
<numero>11 Suppl 1</numero>
<issue>11 Suppl 1</issue>
<page-range>S239-44</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mestres]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gherli]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial]]></article-title>
<source><![CDATA[J Heart Valve Dis]]></source>
<year>2007</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>667-71</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rafiq]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Steinbrüchel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lilleør]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Møller]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thiis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antithrombotic therapy after bioprosthetic aortic valve implantation Warfarin versus aspirin, a randomized controlled trial]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2017</year>
<volume>150</volume>
<page-range>104-10</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Marchena]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mesa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pomenti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombus formation following transcatheter aortic valve replacement]]></article-title>
<collab>Marin Y Kall C.Marincic X.Yahagi K</collab>
<source><![CDATA[JACC Cardiovasc Interv]]></source>
<year>2015</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>728-39</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heras]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chesebro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Penny]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Grill]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High risk of thromboemboli early after bioprosthetic cardiac valve replacement]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1995</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1111-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carnicelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation after heart valve replacement or transcatheter valve implantation]]></article-title>
<collab>O'Gara P.Giugliano R</collab>
<source><![CDATA[Am J Cardiol]]></source>
<year>2016</year>
<volume>118</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1419-26</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moinuddeen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Quin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dewar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tellides]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kopf]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation is unnecessary after biological aortic valve replacement]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1998</year>
<volume>98</volume>
<numero>19 Suppl</numero>
<issue>19 Suppl</issue>
<page-range>II95-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sundt]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zehr]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dearani]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mullany]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[McGregor]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement]]></article-title>
<source><![CDATA[J Thorac Cardiovasc Surg]]></source>
<year>2005</year>
<volume>129</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1024-31</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mérie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Skov Olsen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Andersson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gislason]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Skov Jensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2012</year>
<volume>308</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2118-25</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riaz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Alansari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Riaz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Raza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Luni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and use of anticoagulation after aortic valve replacement with bioprostheses a meta-analysis]]></article-title>
<source><![CDATA[Circ Cardiovasc Qual Outcomes]]></source>
<year>2016</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>294-302</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leetmaa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Leipsic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Poulsen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early aortic transcatheter heart valve thrombosis diagnostic value of contrast-enhanced multidetector computed tomography]]></article-title>
<source><![CDATA[Circ Cardiovasc Interv]]></source>
<year>2015</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakatani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subclinical leaflet thrombosis after transcatheter aortic valve implantation]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2017</year>
<volume>103</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>1942-6</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jilaihawi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Asch]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Manasse]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jelnin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kashif]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic CT methodology for the evaluation of subclinical leaflet thrombosis]]></article-title>
<source><![CDATA[JACC Cardiovasc Imaging]]></source>
<year>2017</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>461-70</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
